Skip to content

Young plasma infusion

Plasma from young donors, sold by the liter as rejuvenation. The FDA warned against it in February 2019 and the best-known seller shut down the next day.

Blood-based therapiesprocedureEarly stage

Availability Regulator warning issued

What it is

Transfusing plasma drawn from young donors into an older person. The idea came from parabiosis, the laboratory technique that joins the circulations of an old mouse and a young one, after which the old animal's tissues repair better. Young plasma infusion was the attempt to sell that result directly, without the surgery and without the mouse.

Why people choose this treatment

It was the most literal rejuvenation product the field has produced: youth, by the liter, from a bag. For a few years around 2017 it also carried a Silicon Valley glamour that made it the story everyone told about longevity medicine.

How it's delivered

It is not, legitimately. Ambrosia, the best-known operation, infused one or two liters over a day or two and charged accordingly, then stopped in February 2019 the day after the FDA published its warning. Plasma transfusion itself remains ordinary medicine for bleeding and immune conditions, which is a different product used for a different reason.

Where the evidence stands

The FDA's statement is unusually plain. There is no proven clinical benefit to infusing young donor plasma for aging or memory loss, or for dementia, Parkinson's, multiple sclerosis, Alzheimer's, heart disease, or post-traumatic stress disorder, and plasma carries infectious, allergic, respiratory, and cardiovascular risks, including lung injury. The one controlled academic trial infused young plasma into eighteen people with Alzheimer's and was designed to test safety and feasibility rather than benefit. The agency reissued its warning after the first notice.

Estimated cost

  • $8,000 for one liter and $12,000 for two at Ambrosia, before it closed
  • No lawful market for the aging use in the United States
  • Plasma transfusion remains standard care for its actual indications
  • Not covered by insurance for aging use

Who offers it

Nobody who should. This entry exists as a caution rather than an option: the marketed version was withdrawn under regulatory pressure, and any clinic still offering it is operating against an explicit federal warning.

Go deeper

The therapeutic plasma exchange guide covers the blood-based approach that does have controlled data behind it, and how it differs from simply adding somebody else's plasma.

Longevity.io is for educational purposes only and is not medical advice. If you have been offered a young plasma infusion, the FDA's own warning is worth reading before anything else, and the conversation belongs with a clinician who knows your situation.

Your Longevity Blueprint

Build your starting plan.

A few short questions, about two minutes. The Blueprint recommends where to start and explains why.

Build my Blueprint